

## **SIGNIFICANT MILESTONE ACHIEVED WITH THE RECRUITMENT OF FIRST SUBJECT FOR EARLY-PHASE CLINICAL TRIAL**

### **HIGHLIGHTS**

- **NeuroScientific has achieved the significant milestone of first subject recruited for its early-phase clinical trial for EmtinB™**
- **This important milestone also signals a major achievement in advancing EmtinB™ as a first-in-class treatment for neurodegenerative conditions, such as Multiple sclerosis and Alzheimer's disease**
- **The early-phase clinical trial will include biomarker studies to assess proof of mechanism activity of EmtinB™ and guide efficacy outcomes in future clinical trials in patients**

NeuroScientific Biopharmaceuticals Ltd (ASX: **NSB**) ("**NeuroScientific**" or "**the company**"), a clinical stage drug development company, is pleased to announce the recruitment of the first subject in its early-phase clinical trial for its lead drug candidate EmtinB™, achieving a significant milestone in the development of EmtinB™ as a first-in-class treatment with disease modifying potential for neurodegenerative conditions, such as Multiple sclerosis and Alzheimer's disease. The early-phase clinical trial is being undertaken by leading WA-based clinical research partner Linear Clinical Research.

**NeuroScientific's Managing Director and Chief Executive Officer Matt Liddelow commented:** "*Following the recent important announcement of securing our first HREC approval for a clinical trial, the recruitment of the first subject for the early-phase clinical trial marks another historic achievement for the Company and a major milestone in developing EmtinB™ as a much needed therapeutic treatment with disease modifying potential for patients with Multiple sclerosis and Alzheimer's disease.*"

The early-phase clinical trial will include up to 30 healthy volunteers. An important focus of this study will involve the assessment of biomarkers in human blood samples that indicate proof of the mechanism of activity of EmtinB™ in humans and can be used to guide efficacy outcomes during future trials in patients.

This announcement is authorised by the Board of NeuroScientific Biopharmaceuticals Ltd.

-ENDS

For more information please contact:

Matthew Liddelow  
CEO and Managing Director  
ml@neuroscientific.com  
+ 61 8 6382 1805

Lucas Robinson  
Investor Relations  
Corporate Storytime  
[lucas@corporatetorytime.com](mailto:lucas@corporatetorytime.com)  
+ 61 408 228 889

#### **About NeuroScientific Biopharmaceuticals Ltd**

NeuroScientific Biopharmaceuticals Limited (ASX: NSB) is a company developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The company's product portfolio includes EmtinB™, a therapeutic peptide initially targeting Alzheimer's disease and glaucoma, as well as other Emtin peptides (EmtinAc, EmtinAn, and EmtinBn) which have demonstrated similar therapeutic potential as EmtinB™. For more information, please visit [www.neuroscientific.com](http://www.neuroscientific.com)

#### **About EmtinB™**

EmtinB™ is a peptide-based compound that binds to surface-based cell receptors from the LDLR family, activating intracellular signalling pathways that stimulate neuroprotection, neuroregeneration and modulate neuroinflammation. EmtinB™ is modelled on a specific active domain of the complex human protein called Metallothionein-IIA, which is produced as part of the human body's innate immune response to cell injury.

Our preclinical research has established that EmtinB™ is highly specific and selective for its target receptor, safe and well tolerated at high concentrations, and is able to penetrate the blood brain barrier. A series of Early-Phase / Phase I clinical studies will be conducted to establish the safety profile of EmtinB™ in humans.